Prognostic Performance of a Modified HFA-ICOS Tool for Prediction of Cardiovascular Complications in Cancer Patients
The tool stratifies CVD risk in cancer patients and may guide tailored follow-up and cardioprotection. Heterogeneity within moderate-risk patients highlights the need for refinement to improve individualized assessment.
Authors
- Siri Lagethon Heck (ORCID: https://orcid.org/0000-0002-5430-1613)
- Håvard Dalen (ORCID: https://orcid.org/0000-0003-1192-3663)
- Mari Nordbø Gynnild (ORCID: https://orcid.org/0000-0001-8623-7911)
- Steven H J Hageman (ORCID: https://orcid.org/0000-0003-2299-6745)
- Espen Holte (ORCID: https://orcid.org/0000-0002-8891-1372)
- Torbjørn Omland (ORCID: https://orcid.org/0000-0002-6452-0369)
- Joris Holtrop (ORCID: https://orcid.org/0009-0005-7616-3839)
- Frank L.J. Visseren (ORCID: https://orcid.org/0000-0003-3951-5223)
- Torgeir Wethal (ORCID: https://orcid.org/0000-0003-0201-3342)
- Jannick A N Dorresteijn
- Geeta Gulati (ORCID: https://orcid.org/0000-0002-1316-8676)
- Sunil Raj
- Unn Merete Fagerli
- Victoria Vinje-Jakobsen
Institutions
- Oslo University Hospital (NO)
- University of Oslo (NO)
- Norwegian University of Science and Technology (NO)
- Akershus University Hospital (NO)
- Levanger Hospital (NO)
- University Medical Center Utrecht (NL)
- St Olav's University Hospital (NO)
Publication Details
- Journal
- JACC Advances
- Published
- 2025-11-17
- DOI
- https://doi.org/10.1016/j.jacadv.2025.102344
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00